跳至主要内容
临床试验/NCT00409903
NCT00409903已完成4 期

The Effect of Eprosartan on Vasoactive Hormones and Renal Tubular Function in Healthy Humans.

Regional Hospital Holstebro2 个研究点 分布在 1 个国家目标入组 18 人开始时间: 2006年11月1日最近更新:
适应症
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
18
试验地点
2
主要终点
Heart rate

研究概览

简要总结

We, the investigators at Holstebro Hospital, want to test the hypothesis that eprosartan reduces the activity of the sympathetic nervous system in healthy individuals - during baseline conditions and after activation of the sympathetic nervous system.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
盲法
Double

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Both genders.
  • Age 18 - 65 years.
  • Body mass index less or equal to 30 kg/m
  • Women must use oral hormonal anticonception, use intrauterine anticonceptive device, be sterilized/hysterectomized or be postmenopausal.

排除标准

  • History or clinical signs of heart, lung, kidney, or endocrine organ disease.
  • Abnormal biochemical screening of the blood regarding: B-hemoglobin, P-sodium, P-potassium, P-creatinine, P-albumin, P-bilirubin, P-alanine aminotransferase, P-alkaline phosphatase, P-cholesterol, and B-glucose.
  • Abnormal screening of the urine regarding: albumin and glucose
  • Malignant disease.
  • Known arterial hypertension or measured 24 hour blood pressure above 135 mmHg systolic or 85 mmHg diastolic.
  • Alcohol abuse.
  • Drug use or abuse.
  • Known intolerance or allergy to eprosartan or sodium nitroprusside.
  • Blood donation within 1 month of the start of the study.

结局指标

主要结局

Heart rate

Fractional sodium excretion

Plasma levels of noradrenaline

次要结局

未报告次要终点

研究者

发起方
Regional Hospital Holstebro
申办方类型
Other

研究点 (2)

Loading locations...

相似试验